Fact CheckerSign in

NCT06652620Active, not recruiting

Cola Ingestion for Esophageal Bolus Impaction

Oral Cola for Acute Food Bolus Impaction in Patients With Esophageal Cancer: a Prospective, Randomized Proof-of-concept Study

Source: ClinicalTrials.gov · Last updated 23 Sept 2026

Brief summary (registry, in English)

The aim of the study is to observe whether cola ingestion can improve the 24-hour remission rate of acute esophageal impaction in patients with esophageal cancer.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
50 (estimated)
First submitted
21 Oct 2024
Start date
1 Nov 2024
Primary completion date
1 Feb 2026
Lead sponsor
Fudan University
NCT number
NCT06652620

What you commit to

  • Study type: Interventional
  • Planned participants: 50
  • From 1 Nov 2024 to the primary completion date, 1 Feb 2026
  • 5 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients who have been diagnosed with or highly suspected of having esophageal fistula through endoscopy or imaging prior to enrollment.
  • Patients who have symptoms such as coughing and are unable to drink cola, or who are at serious risk of aspiration (Glasgow Coma Scale\<14 or previous history of aspiration).
  • Patients with coagulation dysfunction, thrombocytopenia, or taking anticoagulant drugs that are medically considered contraindications for endoscopic examination and treatment.

Other illness

  • Benign diseases such as gastroesophageal reflux, cardiac arrest, and congenital esophageal stenosis that can easily lead to foreign body impaction in the esophagus.

Lab values

  • According to the researchers' assessment, patients may not be able to cooperate with the examination and treatment, or there may be other factors that could force them to terminate the study midway, such as having other serious illnesses (including mental illnesses) that require concomitant treatment, severe abnormal laboratory test values, family or social factors, which may affect the safety of the patients or the collection of experimental data.

Other

  • It is known that complete esophageal obstruction is caused by tumor progression.
  • Patients with nasogastric nutrition tube and esophageal stent implantation

Who the study is looking for

  • Patients with primary esophageal lesions diagnosed by pathology, being able to consume at least a liquid diet normally before and diagnosed by a physician with acute esophageal impaction (acute esophageal impaction refers to the sudden occurrence of complete obstruction of eating within the past week)
  • Prior to enrollment, the patient did not consume carbonated beverages such as cola, or any other treatment for esophageal impaction.
  • Age ≥ 18 years old, Eastern Cooperative Oncology Group (ECOG) Performance Status score is 0-2 points.
  • The subjects voluntarily enrolled and obtained an informed consent form signed by the patient or their legal representative.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (5)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Anyang Tumor Hospital
Coordinator of this site? Confirm its status
AnyangChinaUnknown status
First People's Hospital
Coordinator of this site? Confirm its status
JingdezhenChinaUnknown status
Fudan University Shanghai Cancer Center
Coordinator of this site? Confirm its status
ShanghaiChinaUnknown status
Xiamen University Affiliated First Hospital (Haicang Campus), Xiamen Cancer Hospital
Coordinator of this site? Confirm its status
XiamenChinaUnknown status
The Northern Jiangsu People's Hospital
Coordinator of this site? Confirm its status
YangzhouChinaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.